We are live on ! Find out more
NGM

NGM Biopharmaceuticals, Inc. Common Stock
NGM

Delisted

NGM was delisted on the 4th of April, 2024.

Back to rankings

108 hedge funds and large institutions have $1.25B invested in NGM Biopharmaceuticals, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 39 increasing their positions, 18 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

263% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 8

227% more call options, than puts

Call options by funds: $1.4M | Put options by funds: $430K

117% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 18

23% more funds holding

Funds holding: 88 → 108 (+20)

11% more capital invested

Capital invested by funds: $1.12B → $1.25B (+$127M)

0% more funds holding in top 10

Funds holding in top 10: 7 → 7 (0)

Holders
108
Holders Change
+20
Holders Change %
+22.73%
% of All Funds
1.9%
Holding in Top 10
7
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.12%
New
29
Increased
39
Reduced
18
Closed
8
Calls
$1.4M
Puts
$430K
Net Calls
+$974K
Net Calls Change
+$323K

Top Buyers

Rank Fund Capital Flow
1
RG
Redmile Group
California
+$77M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$13.6M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$11.6M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$10.6M
5
FCM
Farallon Capital Management
California
+$10.5M

Top Sellers

Rank Fund Capital Flow
1
EC
Euclidean Capital
New York
-$16.5M
2
GCP
GSA Capital Partners
United Kingdom
-$1.42M
3
Verition Fund Management
Verition Fund Management
Connecticut
-$1.37M
4
Invesco
Invesco
Georgia
-$1.19M
5
MS
Maven Securities
Jersey
-$1.04M
Name Holding Trade Value Shares
Change 		Change in
Stake
OCA
26
Octagon Capital Advisors
New York
$5.81M +$3.49M +124,773 +166%
JP Morgan Chase
27
JP Morgan Chase
New York
$5.1M -$469K -16,762 -9%
N
28
Nuveen
North Carolina
$5.02M +$2.04M +72,696 +73%
Charles Schwab
29
Charles Schwab
California
$4.77M +$909K +32,474 +25%
Dimensional Fund Advisors
30
Dimensional Fund Advisors
Texas
$4.21M +$2.08M +74,332 +105%
EC
31
EcoR1 Capital
California
$4.17M – – –
Verition Fund Management
32
Verition Fund Management
Connecticut
$3.39M -$1.37M -48,902 -30%
First Trust Advisors
33
First Trust Advisors
Illinois
$2.95M +$2.84M +101,546 New
ACH
34
ArrowMark Colorado Holdings
Colorado
$2.42M +$2.33M +83,333 New
RJA
35
Raymond James & Associates
Florida
$2.35M +$527K +18,817 +30%
Bank of New York Mellon
36
Bank of New York Mellon
New York
$2.32M -$95.2K -3,399 -4%
Two Sigma Investments
37
Two Sigma Investments
New York
$1.98M +$1.91M +68,147 New
MWNA
38
Marshall Wace North America
New York
$1.63M +$1.57M +55,953 New
SAM
39
Silvercrest Asset Management
New York
$1.58M +$1.52M +54,342 New
Goldman Sachs
40
Goldman Sachs
New York
$1.49M +$94K +3,356 +7%
California Public Employees Retirement System
41
California Public Employees Retirement System
California
$1.41M – – –
PPA
42
Parametric Portfolio Associates
Washington
$1.39M +$340K +12,156 +34%
Marshall Wace
43
Marshall Wace
United Kingdom
$1.32M +$1.28M +45,577 New
DekaBank Deutsche Girozentrale
44
DekaBank Deutsche Girozentrale
Germany
$1.29M +$728K +26,000 +123%
UBS Group
45
UBS Group
Switzerland
$1.23M +$669K +23,900 +131%
Aviva
46
Aviva
United Kingdom
$1.22M +$1.18M +42,095 New
California State Teachers Retirement System (CalSTRS)
47
California State Teachers Retirement System (CalSTRS)
California
$1.13M +$76.7K +2,740 +8%
Invesco
48
Invesco
Georgia
$1.01M -$1.19M -42,412 -55%
State of Wisconsin Investment Board
49
State of Wisconsin Investment Board
Wisconsin
$974K – – –
RhumbLine Advisers
50
RhumbLine Advisers
Massachusetts
$828K -$24.1K -860 -3%
1
2
3 4 5

NGM Hedge Fund Activity: Q1 2021 in Review

108 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in NGM Biopharmaceuticals, Inc. Common Stock (NGM) for Q1 2021, worth a combined $1.25B — up 11% from $1.12B a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new NGM positions and 8 closed out — a net gain of 21 holders — while 39 added to existing stakes and 18 trimmed.

The largest buyer was Redmile Group, opening a new position worth an estimated $77M. The largest seller was Euclidean Capital, cutting an estimated $16.5M.

  • 108 institutional investors held NGM Biopharmaceuticals, Inc. Common Stock (NGM) as of Q1 2021, up from 88 in Q4 2020.
  • Funds reported $1.25B of NGM Biopharmaceuticals, Inc. Common Stock stock for Q1 2021, up 11% quarter-over-quarter.
  • 29 funds opened new NGM Biopharmaceuticals, Inc. Common Stock positions in Q1 2021 and 8 closed out, a net change of +21 holders.
  • The largest NGM Biopharmaceuticals, Inc. Common Stock buyer in Q1 2021 was Redmile Group, an estimated $77M added.
  • The largest NGM Biopharmaceuticals, Inc. Common Stock seller in Q1 2021 was Euclidean Capital, an estimated $16.5M sold.

Based on aggregated 13F filings for Q1 2021.